HLA-F and neoplasm: HLA-F may activate or inhibit NK and CD8+T cells by physically interacting with killer-cell immunoglobulin-like receptors (KIRs) such as KIR3DL2, KIR2DS4, and KIR3DS1, indicating that HLA-F may potentially contribute to tumor immune evasion [29,30].